Background-We assessed the role of extracellular signal-regulated kinases (ERKs) in Ang II-stimulated contraction and associated signaling pathways in vascular smooth muscle cells (VSMCs) from human small arteries. Methods and Results-VSMCs derived from resistance arteries (Ͻ300 m in diameter) from subcutaneous gluteal biopsies of healthy subjects (nϭ8) 
T he major function of vascular smooth muscle cells (VSMCs) is to maintain normal vascular tone via coordinated contraction-relaxation cycling. These cells are also responsible for the structural characteristics of the vessel wall, including growth, development, remodeling, and repair. 1 Vascular smooth muscle function is modulated by various growth factors and vasoactive peptides, among which angiotensin II (Ang II) has been identified as an important endogenous regulator. Ang II is a multifunctional peptide that influences both contraction and growth. 2, 3 It binds at least 2 receptors, AT 1 and AT 2 . 4 Most known Ang II-induced effects are mediated via AT 1 receptors, whereas the function and signaling pathways of the AT 2 subtype remain unclear. The AT 1 receptor couples to a wide variety of signal transduction events, including phospholipase C, tyrosine kinases, and mitogen-activated protein kinases (MAPKs) (or extracellular signal-regulated protein kinase [ERK] ). 5 The ERK cascade consists of a 3-kinase module that includes a MAPK (ERK), which in turn is activated by a MAPK/ERK kinase (MEK), which in turn is activated by a MEK kinase (MEKK). 6, 7 Multiple mammalian MAPK pathways have been identified, of which the ERK cascade is the best characterized. It consists of Raf isoforms, MEK1/2, and ERK-1 and ERK-2 and is regulated by Ras. 7, 8 Elucidation of Ang II signaling pathways has been extensively investigated in animal VSMCs. 5, 9 However, little is known about the intracellular transduction events in human VSMCs. The few human studies performed were done in cells from aortic, coronary, internal mammary, umbilical, and uterine arteries and saphenous veins. 10 -17 Furthermore, these studies all examined large vessels, which do not contribute significantly to peripheral resistance or blood pressure regulation. Also, in all of these studies, immortalized or passaged cultured cells, which lose their contractile phenotype and do not resemble the cells from which they were originally derived, were investigated. To the best of our knowledge, there are no data in the literature on Ang II signaling events in VSMCs from human peripheral resistance arteries. The aim of the present study was to investigate the receptor subtypes and some of the intracellular transduction pathways through which Ang II mediates its actions in VSMCs from human peripheral resistance arteries. In particular, we examined whether ERK-dependent pathways play a role in Ang II-elicited second messengers and associated contraction in isolated VSMCs. The novelty of this study relates to the facts that humans, and not experimental animals, were studied; that primary cultured cells, which retain their contractile phenotype, were used; and that small arteries, which contribute to blood pressure regulation, were examined. Furthermore, [Ca 2ϩ ] i and contractile responses were measured simultaneously, which allows for the investigation of the temporal relationship between an intracellular signaling event ([Ca 2ϩ ] i responses) and a functional effector (contraction).
Our study demonstrates that in VSMCs from human peripheral resistance arteries, Ang II-induced contraction and associated second messengers are mediated via receptors of the AT 1 subtype, signaling in part by tyrosine kinases and ERKs. We also show that MEK may influence [Ca 2ϩ ] i by modulating Ca 2ϩ influx and intracellular Ca 2ϩ mobilization. Our data thus show for the first time that in VSMCs from human small arteries, ERK-dependent pathways, which are characteristically involved in signaling cascades associated with cell growth, may also play an important role in Ang II-mediated contraction. These results have important clinical significance, because small arteries are the vessels that play a critical role in regulating peripheral resistance and blood pressure in humans.
Methods

Cell Culture
The study was approved by the Ethics Committee of the Clinical Research Institute of Montreal (IRCM). Written informed consent to participate in the study was obtained from each subject. Healthy men 25 to 50 years old were recruited. They had a normal physical examination, complete blood count, blood biochemistry, and urinalysis. Gluteal biopsies of subcutaneous fat, 1.0ϫ0.5ϫ0.5 cm, were obtained under local anesthesia. Arteries were dissected from gluteal fat under a dissecting microscope immediately after the biopsy had been performed. Small arteries were isolated as previously described. 18 Only vessels with lumen diameters Ͻ300 m were used for cell culture. Vessels of this size correspond to resistance arteries, which contribute significantly to the regulation and distribution of blood flow and pressure. 19 -21 VSMCs were isolated and characterized as described in detail previously, 22, 23 with some modifications. Briefly, cleaned arteries were placed in Ham's F-12 culture medium containing 1% gentamicin, collagenase (type 1), elastase, soybean trypsin inhibitor, and BSA and vortexed in an incubator for 1 hour at 37°C. The digested tissue was further dissociated by repeated aspiration through a syringe (needle gauge, 25). The cell suspension was centrifuged (200g, 5 minutes) and the cell pellet resuspended in Ham's F-12 culture medium containing 10% heat-inactivated FCS. Cells were seeded onto round glass coverslips (25 mm in diameter) that had been coated with Matrigel basement membrane matrix (Becton Dickinson Labware), which is a cell culture preparation optimized for contractile phenotypic states. 24 Matrigel was diluted 1:3 and prepared according to the manufacturer's instructions. For the first 48 hours, cells were incubated in Ham's F-12 culture medium containing 10% heat-inactivated FCS. Thereafter, the culture medium was changed to DMEM containing L-glutamine, HEPES, penicillin, streptomycin, and 0.5% FCS as previously described. 23 Before experimentation, cells were rendered quiescent by serum deprivation and maintenance in a serum-free medium for 36 hours.
For Western blotting of ERKs, cells (passages 1 to 3) from 3 subjects were used. For these studies, cells were grown in DMEM containing heat-inactivated FCS (10%), L-glutamine, HEPES, penicillin, and streptomycin as previously described. 23 VSMCs were maintained at 37°C in a humidified incubator in an atmosphere of 95% air/5% CO 2 . Before experimentation, confluent cultures of VSMCs were rendered quiescent by serum deprivation and maintenance in a serum-free medium for 36 hours.
Measurement of [Ca
] i was measured with fura 2-AM 4 mol/L according to previously described methods. 23 Cells were investigated with an inverted microscope (ϫ40 oil-immersion objective) and Attofluor Digital Fluorescence System (Zeiss) with alternating excitatory wavelengths of 343 and 380 nm. Video images of fluorescence at 520-nm emission were obtained with an intensified CCD camera system with the output digitized to a resolution of 512ϫ480 pixels. [Ca 2ϩ ] i was calculated by in situ calibration techniques. 25 
Measurement of Ang II-Induced Contraction
The gel-coated coverslips with attached fura 2-loaded cells were placed on the stage of the microscope. After a 10-minute stabilization period, a field of cells was photographed to obtain baseline images. Ang II (in the absence or presence of inhibitors) was then added, and serial images were taken of the same field of cells at 30-second intervals after addition of Ang II. The images, which were computer-saved, were later scanned with a Scan Jet 4c/T scanner (Hewlett Packard). The lengths of the longest axes of cells were measured in the first image, and lengths of the same cells were measured in the subsequent photographs with Adobe Photoshop software (version 4.0). The magnitude of cell contraction was expressed as the percentage reduction in cell length relative to initial baseline measurements. 26 -29 For each cell, the percent contraction from the baseline was calculated, and these values were averaged for all cells. To demonstrate that cells did in fact contract in response to Ang II and that the changes in cell length were not simply due to volume changes, we assessed the effects of sodium nitroprusside (SNP), a nitric oxide donor, on Ang II-precontracted cells.
Measurement of pH i
pH i was measured with BCECF-AM 2 mol/L according to previously described methods. 30 Fluorescence was measured with alternating excitatory wavelengths of 488 and 460 nm and an emission wavelength of 520 nm. pH i was calculated from a calibration curve obtained for each experiment by determining the fluorescence ratios at pH i values of 7.4, 7.2, 7.0, and 6.8. pH i was set by incubating the coverslip in K ϩ -rich buffer in the presence of 10 mol/L nigericin (an exogenous K ϩ /H ϩ exchange ionophore). 30 Experimental Protocols [Ca 2ϩ ] i , pH i , and contractile responses were measured in cells exposed to Ang II 10 -12 to 10 Ϫ5 mol/L in the absence and presence of the selective tyrosine kinase inhibitor tyrphostin A- 23 10 Ϫ5 mol/L, its inactive analogue tyrphostin A-1 10 Ϫ5 mol/L, and the MEK inhibitor PD98059 10 Ϫ5 mol/L. 31, 32 For these experiments, cells were preexposed to the specific inhibitors for 20 minutes before addition of Ang II. The effects of SNP were assessed in precontracted cells. In these experiments, once cells had reached maximal contraction (Ϸ3 minutes after addition of Ang II), cells were exposed to 10 Ϫ5 mol/L SNP. 
Western Blotting of ERKs
Quiescent cells, grown on 15 mL-culture plates, were stimulated with Ang II 10 Ϫ7 mol/L for 1.5, 3, 5, or 10 minutes. Cells were pretreated with 10 Ϫ5 mol/L PD98059 for 30 minutes before Ang II addition. Cells were lysed, collected, and sonicated for 5 seconds as previously described. 6 Protein concentrations were determined with the Bio-Rad Assay (Bio-Rad Laboratories). Equal amounts of proteins (15 g for phosphotyrosine assays and 5 g for ERK assessment) were loaded onto a 10% SDS-polyacrylamide gel and transferred to PVDF membrane (Boehringer Mannheim) for 1 hour at 100 V. Membranes were blocked in 5% nonfat milk (for ERK) or 5% BSA (for phosphotyrosine) and incubated with anti-ERK1 diluted 1:5000 or a mouse antibody anti-phosphotyrosine (PY20) diluted 1:750 for 1 hour at room temperature. They were then washed, incubated with a goat anti-rabbit horseradish peroxidaseconjugated antibody (Bio-Rad) (for ERK) or a goat anti-mouse horseradish peroxidase-conjugated antibody (for phosphotyrosine) diluted 1:5000 for 1 hour at room temperature, and washed extensively. Membranes were then incubated with blotting substrate (POD) (Boehringer Mannheim) according to the manufacturer's protocol, exposed to film, and developed. The film was scanned by ScanJet 6100C/T (Hewlett Packard) and computer-saved. Band intensity was measured by computer analysis with the Image Quant program. (Figure 1 ). The first phase, which peaked within a few seconds after addition of Ang II, was acute and transient ( Figure 1 ). The second [Ca 2ϩ ] i phase was sustained at suprabasal levels ( Figure 1 (Figure 2 ). Ang II dose-dependently increased pH i (pD 2 ϭ9.4Ϯ0.29 and E max ϭ7.19Ϯ0.01) ( Figure  2 ). pH i values at maximal alkalinization were used to construct dose-response curves. (Figures 1 and 3 ) and prolonged [Ca 2ϩ ] i recovery to basal levels ( Figure 1 ). Tyrphostin A-23 significantly attenuated (PϽ0.05) Ang II-stimulated alkalinization (Figure 4) . Tyrphostin A-1 had no effect on agoniststimulated responses (Figures 1, 3, and 4) . These data suggest that Ang II-elicited actions are partially mediated through tyrosine kinase-dependent pathways.
Statistical Analysis
Effects of Tyrphostin
PD98059 (Figure 5) . These results were similar to those obtained with PD98059 in the presence of extracellular Ca 2ϩ . 
Effects of Ang II on VSMC Contraction
Ang II dose-dependently reduced cell length (pD 2 ϭ9.2Ϯ0.21, E max ϭ36Ϯ2.2%) ( 
Characterization of Human VSMC Angiotensin Receptors
[Sar 1 ,Ile 8 ]Ang II (a nonspecific angiotensin subtype receptor antagonist) and losartan (a selective AT 1 receptor antagonist) completely abolished Ang II-mediated responses ( Figure 9 ). PD123319 (a selective AT 2 antagonist) had no effect on Ang II-stimulated effects ( Figure 9 ). Treatment of VSMCs with any of the antagonists alone did not influence basal [Ca 2ϩ ] i , pH i , or cell size.
Effects of PD98059 on Ang II Effects on ERK Expression and Tyrosine Phosphorylation
To determine whether Ang II-induced changes in ERK expression and tyrosine phosphorylation could occur within a time frame that would be responsible for early signal transduction events and to assess whether PD98059 could attenuate these effects, cells were incubated for various periods of time with Ang II, in the absence and presence of PD98059, before cell lysis. Multiple proteins were tyrosine-phosphorylated under basal conditions. Ang II significantly increased tyrosine phosphorylation of 2 proteins with molecular 
Discussion
Data from the present study demonstrate that VSMCs from human peripheral resistance arteries possess functional angiotensin receptors of the AT 1 subtype that mediate contraction via signaling cascades involving Ca 2ϩ and pH i pathways that are partially dependent on tyrosine kinases and ERKs. Our results suggest that ERKs probably influence [Ca 2ϩ ] i by modulating Ca 2ϩ influx and intracellular Ca 2ϩ mobilization. Smooth muscle cells in culture are used routinely in an effort to elucidate the causes and mechanisms of vascular disease. However, cells in culture, especially serially passaged cells, undergo many phenotypic and morphological changes. Accordingly, cultured cells may be very different from the cells from which they were originally derived. In the present work, we studied cells that had undergone little phenotypic change relative to the native cells in blood vessels. Primary cultured cells were grown on Matrigel basement membrane matrix in low-serum-containing culture medium. Under these conditions, they displayed a contractile phenotype, had a low proliferation rate, expressed the cytoskeletal marker ␣-actin as determined by immunocytochemical analysis, and contracted in response to Ang II. These features are characteristic of the contractile phenotype as previously described. 25 An important issue in this study is the VSMC contraction in response to Ang II. Cell volume changes could theoretically imitate contraction, 27 and in the present study, actinmyosin interaction was not directly evaluated to unambiguously demonstrate that contraction had occurred. The fact that cells shortened in response to Ang II and elongated when exposed to SNP suggests that the cells did carry out excitation-contraction coupling and were probably under tension during the shortening phase. With respect to cell shape changes, we did not notice any ballooning of the cell bodies after exposure to Ang II, indicating that the physical change cells underwent was not simply a change in the shape of the cell. Thus, cell shortening induced by Ang II in our study probably does reflect smooth muscle cell contraction.
[Ca 2ϩ ] i is a major trigger of actin-myosin interaction, cross-bridge cycling, and VSMC contraction. 33 The response elicited by Ang II was typically biphasic, with an acute peak followed by a sustained, suprabasal second phase. The second [Ca 2ϩ ] i phase was temporally related to maximum contraction, indicating an association between [Ca 2ϩ ] i and contraction. pH i is also an important second messenger. Intracellular alkalinization stimulates DNA synthesis and cell growth and increases actin-myosin sensitivity to Ca 2ϩ , thereby increasing vascular contraction and tone. 34 Basal pH i in the present study was similar to that reported in the only other known study of pH i in cultured human VSMCs 35 and to the pH i in intact human subcutaneous small arteries. 36 Our results, which are the first to show that Ang II induces alkalinization in primary cultured human VSMCs, are in agreement with findings from rat studies. 28, 37 In addition to stimulation of classic phospholipase C-mediated Ca 2ϩ signaling pathways, Ang II also stimulates protein phosphorylation on tyrosine residues. 38, 39 Tyrosine kinase pathways are typically involved in cell growth, and it has recently been shown that these pathways also modulate contraction. 3, 28 To determine whether tyrosine kinases regulate VSMC [Ca 2ϩ ] i and pH i , we assessed Ang II effects in the presence of the selective tyrosine kinase inhibitor tyrphostin A-23 and its inactive analogue tyrphostin A-1. Tyrphostin A-23, but not tyrphostin A-1, attenuated Ang II-elicited actions, suggesting a contribution of tyrosine kinases in the regulation of agonist-stimulated responses in human VSMCs. The tyrosine kinase effects on Ang II-elicited pH i responses may be mediated via Na ϩ -H ϩ -linked pathways. We have observed in rat VSMCs that activity of the Na ϩ -H ϩ exchanger is reduced by tyrosine kinase inhibitors. The importance of tyrosine phosphorylation in Ang II signaling has been extensively reviewed recently. 5, 6 The quoted studies, however, all referred to animal experiments. Our data now demonstrate that tyrosine kinases are also implicated in Ang II-mediated Ca 2ϩ and pH i signaling in human VSMCs. The specific tyrosine kinase effectors involved in Ang II-stimulated responses are unclear, but ERKs may play a role, because they have been implicated in both contraction and growth in rat VSMCs. 3, 5, 6, 40 The immediate ERK activator is MEK, which phosphorylates ERK-1 and ERK-2. 41, 42 MEK, in turn, is activated by various kinases, which are stimulated by Ang II in cultured VSMCs. 43, 44 Thus, MEK may be a potential tyrosine kinase candidate activated by Ang II. To assess the role of ERKs in Ang II signaling, the MEK inhibitor PD98059 was used. We demonstrated that PD98059 inhibited Ang II-stimulated ERK activity in VSMCs, indicating that the inhibitor did in fact block agonist-induced ERK activation and that it was effective at a concentration of 10 Ϫ5 mol/L. In cells pretreated with PD98059, Ang IIelicited alkalinization was reduced, [Ca 2ϩ ] i peak responses were attenuated, the second [Ca 2ϩ ] i phase was inhibited, and contraction was significantly decreased. These data suggest that ERKs partially regulate Ang II-stimulated second messengers and associated contraction in human VSMCs. -free buffer suggests that MEK inhibition may also elicit its effects via another mechanism, possibly by inhibition of Ca 2ϩ mobilization. These data are supported by recent studies that demonstrated that Ang II-induced inositol phosphate generation is mediated through tyrosine kinase pathways in cardiomyocytes 45 and that tyrosine kinases activate voltage-dependent Ca 2ϩ channels in vascular smooth muscle. 46 It may also be possible that ERKs directly influence regulatory contractile proteins. 47 However, the exact cellular pathways by which ERKs influence Ang II-mediated signaling and contraction in VSMCs await further clarification.
Ang receptor subtypes mediating Ang II responses were characterized by use of selective receptor antagonists.
[Sar 1 ,Ile 8 ]Ang II and losartan completely blocked the cellular effects of Ang II, whereas PD123319 had no effect. These results indicate that Ang II-elicited actions are exclusively of the AT 1 subtype in human VSMCs. Similar results have been reported in cultured cells from human coronary arteries and saphenous vein as well as in cells from rat small arteries. 4, 10, 13, 28 In conclusion, this study provides the novel findings that in VSMCs, ERKs modulate Ang II-induced contraction and signaling events that lie upstream from MEK. These effects are mediated via AT 1 receptors. Our data have significant physiological implications, because the cells that we studied retained their contractile phenotype so that they resembled, as closely as possible, the cells of origin. Also, cells were derived from peripheral resistance arteries, vessels that contribute to peripheral resistance and blood pressure regulation. The present study thus provides new insights regarding Ang II signaling in VSMCs, which participate in mechanisms involved in the control of blood pressure through changes in peripheral resistance in humans.
